These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 33966377)

  • 1. Nano- and Microformulations to Advance Therapies for Visceral Leishmaniasis.
    Varma DM; Redding EA; Bachelder EM; Ainslie KM
    ACS Biomater Sci Eng; 2021 May; 7(5):1725-1741. PubMed ID: 33966377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The preclinical discovery and development of oral miltefosine for the treatment of visceral leishmaniasis: a case history.
    Reimão JQ; Pita Pedro DP; Coelho AC
    Expert Opin Drug Discov; 2020 Jun; 15(6):647-658. PubMed ID: 32202449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of BTK Inhibitor Ibrutinib on Leishmania infantum Infection In Vitro.
    Mert U; Müftüoğlu C; Erdem S; Sadıqova A; Toz S; Ozbel Y; Caner A
    Acta Parasitol; 2022 Dec; 67(4):1732-1739. PubMed ID: 36260194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hit-to-lead optimization of 2-aminoquinazolines as anti-microbial agents against Leishmania donovani.
    Das N; Roy J; Patra B; Saunders E; Sarkar D; Goon S; Sinha BP; Roy S; Roy S; Sarif J; Bandopadhyay P; Barik S; Mukherjee S; McNamara N; Varghese S; Simpson K; Baell J; McConville M; Ganguly D; Talukdar A
    Eur J Med Chem; 2024 Apr; 269():116256. PubMed ID: 38461679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visceral leishmaniasis caused by Leishmania (Leishmania) amazonensis associated with Hodgkin's lymphoma.
    Porto VBG; Carvalho LB; Buzo BF; Litvoc MN; Santos ACS; Rocci RA; Soares SRC; Zampieri RA; Duarte MIS; Lindoso JAL
    Rev Inst Med Trop Sao Paulo; 2022; 64():e51. PubMed ID: 36074446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of growth arrested Leishmania amastigotes: a tool to develop live attenuated vaccine candidates against visceral leishmaniasis.
    Selvapandiyan A; Dey R; Gannavaram S; Solanki S; Salotra P; Nakhasi HL
    Vaccine; 2014 Jun; 32(31):3895-901. PubMed ID: 24837513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Host resistance to visceral leishmaniasis: prevalence and prevention.
    Maran N; Gomes PS; Freire-de-Lima L; Freitas EO; Freire-de-Lima CG; Morrot A
    Expert Rev Anti Infect Ther; 2016; 14(4):435-42. PubMed ID: 26934623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition.
    Wyllie S; Brand S; Thomas M; De Rycker M; Chung CW; Pena I; Bingham RP; Bueren-Calabuig JA; Cantizani J; Cebrian D; Craggs PD; Ferguson L; Goswami P; Hobrath J; Howe J; Jeacock L; Ko EJ; Korczynska J; MacLean L; Manthri S; Martinez MS; Mata-Cantero L; Moniz S; Nühs A; Osuna-Cabello M; Pinto E; Riley J; Robinson S; Rowland P; Simeons FRC; Shishikura Y; Spinks D; Stojanovski L; Thomas J; Thompson S; Viayna Gaza E; Wall RJ; Zuccotto F; Horn D; Ferguson MAJ; Fairlamb AH; Fiandor JM; Martin J; Gray DW; Miles TJ; Gilbert IH; Read KD; Marco M; Wyatt PG
    Proc Natl Acad Sci U S A; 2019 May; 116(19):9318-9323. PubMed ID: 30962368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Multiplexed Assay for Detection of
    Abeijon C; Alves F; Monnerat S; Wasunna M; Mbui J; Viana AG; Bueno LL; Siqueira WF; Carvalho SG; Agrawal N; Fujiwara R; Sundar S; Campos-Neto A
    J Clin Microbiol; 2019 May; 57(5):. PubMed ID: 30787142
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Ramalingam K; Gangwar S; Balodi DC; Anand A; Yadav S; Biswas S; Karunakaran Sasikala AK; Gupta KC; Batra S; Goyal N
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0236121. PubMed ID: 35852367
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Chang L; Che G; Yang Q; Lai S; Teng J; Duan J; Liu T; Liu F
    Front Public Health; 2023; 11():1197149. PubMed ID: 37435524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urine-based antigen detection assay for diagnosis of visceral leishmaniasis using monoclonal antibodies specific for six protein biomarkers of Leishmania infantum / Leishmania donovani.
    Abeijon C; Alves F; Monnerat S; Mbui J; Viana AG; Almeida RM; Bueno LL; Fujiwara RT; Campos-Neto A
    PLoS Negl Trop Dis; 2020 Apr; 14(4):e0008246. PubMed ID: 32324742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemisynthetic trifluralin analogues incorporated in liposomes for the treatment of leishmanial infections.
    Carvalheiro M; Esteves MA; Santos-Mateus D; Lopes RM; Rodrigues MA; Eleutério CV; Scoulica E; Santos-Gomes G; Cruz ME
    Eur J Pharm Biopharm; 2015 Jun; 93():346-52. PubMed ID: 25936854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic options for visceral leishmaniasis.
    Monge-Maillo B; López-Vélez R
    Drugs; 2013 Nov; 73(17):1863-88. PubMed ID: 24170666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and Serological Evidence of Leishmania Infection in Stray Dogs from Visceral Leishmaniasis-Endemic Areas of Bangladesh.
    Akter S; Alam MZ; Nakao R; Yasin G; Kato H; Katakura K
    Am J Trop Med Hyg; 2016 Oct; 95(4):795-799. PubMed ID: 27382083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
    Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M
    mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leishmaniasis in Turkey: Visceral and cutaneous leishmaniasis caused by Leishmania donovani in Turkey.
    Özbilgin A; Harman M; Karakuş M; Bart A; Töz S; Kurt Ö; Çavuş İ; Polat E; Gündüz C; Van Gool T; Özbel Y
    Acta Trop; 2017 Sep; 173():90-96. PubMed ID: 28587839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanomedicines for Therapy of Visceral Leishmaniasis.
    Want MY; Yadav P; Afrin F
    J Nanosci Nanotechnol; 2016 Mar; 16(3):2143-51. PubMed ID: 27455613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Miltefosine and Nifuratel Combination: A Promising Therapy for the Treatment of
    Melcon-Fernandez E; Galli G; García-Estrada C; Balaña-Fouce R; Reguera RM; Pérez-Pertejo Y
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis.
    Costa RR; Oliveira-da-Silva JA; Reis TAR; Tavares GSV; Mendonça DVC; Freitas CS; Lage DP; Martins VT; Antinarelli LMR; Machado AS; Bandeira RS; Ludolf F; Santos TTO; Brito RCF; Humbert MV; Menezes-Souza D; Duarte MC; Chávez-Fumagalli MA; Roatt BM; Coimbra ES; Coelho EAF
    Med Microbiol Immunol; 2021 Jun; 210(2-3):133-147. PubMed ID: 33870453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.